Ertugrul Guclu1, Aziz Ogutlu1, Oguz Karabay1. 1. Department of Infectious Diseases and Clinical Microbiology, Sakarya University School of Medicine, Sakarya, Turkey.
Abstract
OBJECTIVE: There are a limited number of studies on the seroprevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection in Turkey. This study aimed to compare HBV and HCV seroprevalence rates before and after the implementation of national hepatitis B vaccination program (NHPVP) and to explore age-related changes in the seroprevalences. MATERIALS AND METHODS: Results of Hepatitis B surface antigen (HBsAg), Hepatitis B virus surface antibody (antiHBs) and anti-HCV tests performed during 2009 and 2010 in a state hospital laboratory were reviewed retrospectively. As NHPVP was started in 1998, 12 years of age and younger children were considered post- NHPVP period subjects. RESULTS: A total of 3280 HBsAg, 2444 antiHBs and 3188 anti-HCV test results were reviewed, representing approximately 3% of the population of the city where the study was conducted. HBsAg, antiHBs and anti-HCV positivity were 3.2%, 36.12% and 0.97%, respectively. HBsAg and antiHBs positivity were higher among males (p<0.001). When assessed by age groups, HBsAg positivity was found to be the lowest in the age group 0-12 and highest in the age group 51-60. HBsAg positivity was lower in the post-NHPVP period versus pre-NHPVP period (p=0.01). Anti-HCV positivity was similar for pre- and post- NHPVP periods (p>0.05). CONCLUSION: Owing to the use of NHPVP, HBsAg seropositivity has decreased, and it is expected to decrease further in the next years with a wider implementation of the program. Efforts should be continued to increase the level of awareness in the community for HBV and the importance of immunization.
OBJECTIVE: There are a limited number of studies on the seroprevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection in Turkey. This study aimed to compare HBV and HCV seroprevalence rates before and after the implementation of national hepatitis B vaccination program (NHPVP) and to explore age-related changes in the seroprevalences. MATERIALS AND METHODS: Results of Hepatitis B surface antigen (HBsAg), Hepatitis B virus surface antibody (antiHBs) and anti-HCV tests performed during 2009 and 2010 in a state hospital laboratory were reviewed retrospectively. As NHPVP was started in 1998, 12 years of age and younger children were considered post- NHPVP period subjects. RESULTS: A total of 3280 HBsAg, 2444 antiHBs and 3188 anti-HCV test results were reviewed, representing approximately 3% of the population of the city where the study was conducted. HBsAg, antiHBs and anti-HCV positivity were 3.2%, 36.12% and 0.97%, respectively. HBsAg and antiHBs positivity were higher among males (p<0.001). When assessed by age groups, HBsAg positivity was found to be the lowest in the age group 0-12 and highest in the age group 51-60. HBsAg positivity was lower in the post-NHPVP period versus pre-NHPVP period (p=0.01). Anti-HCV positivity was similar for pre- and post- NHPVP periods (p>0.05). CONCLUSION: Owing to the use of NHPVP, HBsAg seropositivity has decreased, and it is expected to decrease further in the next years with a wider implementation of the program. Efforts should be continued to increase the level of awareness in the community for HBV and the importance of immunization.
Entities:
Keywords:
Seroprevalence; vaccination; viral Hepatitis B; viral hepatitis C
Authors: Eric E Mast; Harold S Margolis; Anthony E Fiore; Edward W Brink; Susan T Goldstein; Susan A Wang; Linda A Moyer; Beth P Bell; Miriam J Alter Journal: MMWR Recomm Rep Date: 2005-12-23
Authors: A Hatzakis; P Van Damme; K Alcorn; C Gore; M Benazzouz; S Berkane; M Buti; M Carballo; H Cortes Martins; S Deuffic-Burban; A Dominguez; M Donoghoe; A-N Elzouki; N Ben-Alaya Bouafif; G Esmat; R Esteban; M Fabri; K Fenton; D Goldberg; I Goulis; C Hadjichristodoulou; T Hadjichristodoulou; T Hatzigeorgiou; O Hamouda; S Hasurdjiev; S Hughes; A Kautz; M Malik; S Manolakopoulos; M Matičič; G Papatheodoridis; R Peck; A Peterle; G Potamitis; D Prati; F Roudot-Thoraval; T Reic; A Sharara; M Shennak; G Shiha; D Shouval; M Sočan; H Thomas; M Thursz; M Tosti; C Trépo; A Vince; E Vounou; L Wiessing; M Manns Journal: J Viral Hepat Date: 2013-08 Impact factor: 3.728
Authors: Entisar A Murad; Suad M Babiker; Gasim I Gasim; Duria A Rayis; Ishag Adam Journal: BMC Pregnancy Childbirth Date: 2013-06-07 Impact factor: 3.007
Authors: Juliane Girão de Moura; Bruno Almeida Costa; Fabiana Aguiar Carneiro Silva; Francisco Vagnaldo Fechine; Ênio Simas Macedo; José Lucio Jorge Barbosa; Franklin José Candido Santos; Elizabeth de Francesco Daher; Luciana Maria de Barros Carlos; Denise Menezes Brunetta Journal: Health Sci Rep Date: 2021-10-14